Ipragliflozin Add-On Therapy to a Glp-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
Hisamitsu Ishihara
Susumu Yamaguchi
Ikko Nakao
Taishi Sakatani
10.6084/m9.figshare.6395915.v1
https://adisjournals.figshare.com/articles/figure/Ipragliflozin_Add-On_Therapy_to_a_Glp-1_Receptor_Agonist_in_Japanese_Patients_with_Type_2_Diabetes_AGATE_A_52-Week_Open-Label_Study/6395915
<p><b>AGATE:</b>
A long-term study to show efficacy and safety of ipragliflozin in <b><u>A</u></b>dd-on therapy with <b><u>G</u></b>LP-1 receptor <b><u>A</u></b>gonists in <b><u>T</u></b>ype 2 diabet<b><u>E</u></b>s mellitus patients</p><p><br></p><p>
</p><p><b>Article full text</b></p><p><br></p><p>The full text of this article can
be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s13300-018-0455-8">https://link.springer.com/article/10.1007/s13300-018-0455-8</a></p><p></p><p><br></p><p><b>Provide enhanced content for this
article</b></p><p><br></p><p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/âmailto:adisrapidplus@springer.comâ"><b>adisrapidplus@springer.com</b></a>.</p><p><br></p><p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as ‘peer reviewed’ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p><p><br></p><p>Other enhanced features include,
but are not limited to:</p><p><br></p><p>• Slide decks</p><p>• Videos and animations</p><p>• Audio abstracts</p><p>
</p><p>• Audio slides</p>
<p> </p>
<p><b> </b></p>
<b><br>
</b>
<p><b> </b></p><br><p></p>
2018-06-15 14:44:38
Diabetes Mellitus, Type 2
Glucagon-Like Peptide-1 Receptor
Ipragliflozin
Sodium-Glucose Transporter 2